CRISM Therapeutics (CRTX) Competitors GBX 11 -1.00 (-8.33%) (As of 12/20/2024 11:48 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitors CRTX vs. EMH, LND, CLA, KAV, GLR, PXC, BRES, ARV, TGR, and FRGShould you be buying CRISM Therapeutics stock or one of its competitors? The main competitors of CRISM Therapeutics include European Metals (EMH), Landore Resources (LND), Celsius Resources (CLA), Kavango Resources (KAV), Galileo Resources (GLR), Phoenix Copper (PXC), Blencowe Resources (BRES), Artemis Resources (ARV), Tirupati Graphite (TGR), and Firering Strategic Minerals (FRG). These companies are all part of the "other industrial metals & mining" industry. CRISM Therapeutics vs. European Metals Landore Resources Celsius Resources Kavango Resources Galileo Resources Phoenix Copper Blencowe Resources Artemis Resources Tirupati Graphite Firering Strategic Minerals CRISM Therapeutics (LON:CRTX) and European Metals (LON:EMH) are both small-cap basic materials companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, community ranking, dividends and institutional ownership. Is CRTX or EMH more profitable? European Metals' return on equity of -9.61% beat CRISM Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CRISM TherapeuticsN/A -62.67% -26.77% European Metals N/A -9.61%-2.47% Which has more volatility and risk, CRTX or EMH? CRISM Therapeutics has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, European Metals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Which has higher earnings and valuation, CRTX or EMH? CRISM Therapeutics has higher earnings, but lower revenue than European Metals. European Metals is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCRISM TherapeuticsN/AN/A-£1.77M£8.221.34European Metals£1.54M9.50-£3.36M-£0.01-705.00 Does the MarketBeat Community prefer CRTX or EMH? CRISM Therapeutics and European Metals both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformCRISM TherapeuticsN/AN/AEuropean MetalsN/AN/A Does the media prefer CRTX or EMH? In the previous week, CRISM Therapeutics' average media sentiment score of 0.00 equaled European Metals'average media sentiment score. Company Overall Sentiment CRISM Therapeutics Neutral European Metals Neutral Do insiders & institutionals have more ownership in CRTX or EMH? 11.7% of European Metals shares are owned by institutional investors. 68.8% of CRISM Therapeutics shares are owned by company insiders. Comparatively, 0.3% of European Metals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryEuropean Metals beats CRISM Therapeutics on 5 of the 9 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get CRISM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRTX vs. The Competition Export to ExcelMetricCRISM TherapeuticsOther Industrial Metals & Mining IndustryMaterials SectorLON ExchangeMarket Cap£3.60M£847.77M£2.85B£1.90BDividend YieldN/A6.19%5.02%5.45%P/E Ratio1.3458.88112.721,863.09Price / SalesN/A54,859.15800,113.13392,686.74Price / CashN/A25.0224.4128.61Price / Book1.832.383.412.80Net Income-£1.77M£57.93M£152.72M£155.77M7 Day Performance-6.38%-2.66%-2.91%-2.02%1 Month Performance22.22%17.00%1.16%21.64%1 Year PerformanceN/A24.58%17.15%29.70% CRISM Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRTXCRISM TherapeuticsN/AGBX 11-8.3%N/AN/A£3.60MN/A1.344Gap UpEMHEuropean MetalsN/AGBX 7+3.7%N/A-72.1%£14.52M£1.54M-700.00N/ALNDLandore ResourcesN/AGBX 4.35flatN/A+24.1%£13.61MN/A-435.006CLACelsius ResourcesN/AGBX 0.50+5.3%N/A-26.2%£12.85M£647.000.00N/ANews CoverageGap DownKAVKavango ResourcesN/AGBX 0.70+3.7%N/A-0.3%£10.92MN/A-3.1943Gap DownGLRGalileo ResourcesN/AN/AN/A-20.0%£10.21MN/A-13.001High Trading VolumePXCPhoenix CopperN/AGBX 5flatN/A-77.6%£9.23MN/A-500.0018Gap UpBRESBlencowe ResourcesN/AGBX 3.95+2.6%N/A-14.9%£8.94MN/A-395.003Gap UpARVArtemis ResourcesN/AGBX 0.45flatN/A-64.5%£8.64MN/A-44.00N/ANews CoverageGap DownTGRTirupati GraphiteN/AGBX 6.25flatN/AN/A£8.09M£4.96M107.6736,000FRGFirering Strategic MineralsN/AGBX 4.20-6.7%N/A-6.5%£7.74M£1.61M-140.00N/A Related Companies and Tools Related Companies European Metals Alternatives Landore Resources Alternatives Celsius Resources Alternatives Kavango Resources Alternatives Galileo Resources Alternatives Phoenix Copper Alternatives Blencowe Resources Alternatives Artemis Resources Alternatives Tirupati Graphite Alternatives Firering Strategic Minerals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:CRTX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISM Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
